Trials / Unknown
UnknownNCT02352792
Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer
Randomized Phase II Study for Dose Escalation in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated With Radiochemotherapy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with locally advanced suqamous cell carcinoma of the head and neck region receive a hypoxia scan either by magnetic resonance tomography, computed tomography or fluoromisonidazole (FMISO)-PET-CT. Patients presenting with hypoxia are randomized into standard therapy consisting of intensity modulated radiotherapy (IMRT) with 70 Gy plus either 5-fluorouracil/mitomycin C or cisplatinum (Arm A) or a dose escalation of 10% (77Gy) to the hypoxic volume applied via simultaneous integrated boost in addition to the standard treatment (Arm B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | radiochemotherapy with 70 Gy | |
| RADIATION | radiochemotherapy with 77 Gy |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2017-12-01
- Completion
- 2022-12-01
- First posted
- 2015-02-02
- Last updated
- 2015-02-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02352792. Inclusion in this directory is not an endorsement.